Bio-Rad Laboratories, Inc. (NYSE:BIO) to Post FY2022 Earnings of $14.35 Per Share, Jefferies Financial Group Forecasts

Bio-Rad Laboratories, Inc. (NYSE:BIOGet Rating) – Equities research analysts at Jefferies Financial Group boosted their FY2022 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a research report issued on Sunday, July 31st. Jefferies Financial Group analyst B. Couillard now forecasts that the medical research company will post earnings per share of $14.35 for the year, up from their prior estimate of $14.20. Jefferies Financial Group has a “Buy” rating and a $700.00 price target on the stock. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $14.20 per share. Jefferies Financial Group also issued estimates for Bio-Rad Laboratories’ Q4 2022 earnings at $3.44 EPS, Q1 2023 earnings at $3.63 EPS, Q2 2023 earnings at $4.46 EPS and Q3 2023 earnings at $3.55 EPS.

A number of other research analysts also recently weighed in on BIO. Citigroup decreased their price target on Bio-Rad Laboratories from $750.00 to $700.00 and set a “buy” rating for the company in a research note on Friday, July 8th. TheStreet downgraded Bio-Rad Laboratories from a “b-” rating to a “c+” rating in a research note on Thursday, April 28th.

Bio-Rad Laboratories Stock Up 0.1 %

BIO stock opened at $548.55 on Wednesday. The company has a quick ratio of 4.22, a current ratio of 5.30 and a debt-to-equity ratio of 0.13. The business has a 50 day moving average price of $513.14 and a two-hundred day moving average price of $546.71. The company has a market cap of $16.42 billion, a price-to-earnings ratio of -8.27 and a beta of 0.96. Bio-Rad Laboratories has a twelve month low of $462.61 and a twelve month high of $832.70.

Bio-Rad Laboratories (NYSE:BIOGet Rating) last announced its earnings results on Thursday, July 28th. The medical research company reported $3.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.46 by $0.92. Bio-Rad Laboratories had a positive return on equity of 3.82% and a negative net margin of 67.66%. The business had revenue of $691.10 million for the quarter, compared to analyst estimates of $664.60 million. During the same quarter last year, the firm earned $3.54 EPS. Bio-Rad Laboratories’s revenue for the quarter was down 3.5% compared to the same quarter last year.

Institutional Trading of Bio-Rad Laboratories

Institutional investors have recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust raised its holdings in Bio-Rad Laboratories by 80.0% in the 2nd quarter. Parkside Financial Bank & Trust now owns 54 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 24 shares in the last quarter. HM Payson & Co. acquired a new position in Bio-Rad Laboratories in the 1st quarter valued at $28,000. Cambridge Trust Co. raised its holdings in Bio-Rad Laboratories by 170.0% in the 1st quarter. Cambridge Trust Co. now owns 54 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 34 shares in the last quarter. Sageworth Trust Co of South Dakota acquired a new position in Bio-Rad Laboratories in the 4th quarter valued at $43,000. Finally, Tcwp LLC acquired a new position in Bio-Rad Laboratories in the 1st quarter valued at $48,000. 63.66% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Company Profile

(Get Rating)

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Featured Articles

Earnings History and Estimates for Bio-Rad Laboratories (NYSE:BIO)

Want More Great Investing Ideas?

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.